Publication details
Economic impact of type 2 diabetes and diabetes-associated complications: a large claims-based study
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | The overall sample size consisted of 62,895 patients with T2DM. Out of the total patient population, 52% had no complications, 22% only microvascular, 13% only macrovascular and 14% both micro- and macrovascular complications. From a health-care payer perspective, there was a steady increase in the mean total costs per diabetic patient per year (pppy), from €878 in 2013 to €1,264 in 2017 (+44%). In 2013, medicines were the major contributor to direct costs (56%). However, this proportion gradually declined until it reached 49% in 2017. Other main drivers of costs were hospital care (14%), medical devices (8%) and outpatient care (7%). The mean total direct costs pppy were 1) €656 (without complications; denoted as baseline), 2) €1,058 (microvascular complications; +61% relative to baseline costs without complications), 3) €1,281 (macrovascular complications; +95%) 4) €2,025 (micro- and macrovascular complications; +209%). |